🔗 Share this article

As the US continues making sweeping changes to its vaccine recommendations, an unexpected name has emerged somewhat surprisingly: Høeg, a US-based sports physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots throughout the global health crisis and has zeroed in on potential deaths after Covid vaccination in her short tenure at the FDA.

Proposed Shifts to Childhood Immunization Program

Health officials planned to announce major changes to the childhood vaccination calendar recently, bringing the US with Denmark’s vaccine program, according to reports – a significant shift that would place the US out of alignment with a large portion of the international standard with little proof for benefit. The planned update has been pushed back until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is set to address the audience at the gathering. She was just designated acting director of the FDA’s CDER, the fifth individual to lead the division this year.

A New Direction at the Agency

Høeg's temporary position could signify a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it suggests a renewed priority upon reevaluating long-standing immunizations at the FDA.

Høeg has frequently advocated for halting specific childhood vaccine recommendations in the US to become more in line with Denmark's approach, a nation with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccines – usually the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Concerns Over Qualifications

Høeg has no obvious background in drug development, approval processes or leadership, which has been standard for former heads of the biologics center. She has worked at the FDA as a key advisor to the agency head and CBER since March.

“She appears not to have the necessary background” for running the CDER, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She lacks experience in leading a sizeable institution. She has no expertise in industry regulation.”

Former heads of CBER would “grasp legal statutes and the research of medication creation”, said a former acting FDA commissioner. “Frankly, she lacks the kind of background that former directors who led CBER have had.”

The drug center has an enormous workload at the FDA, Woodcock emphasized.

“Everybody just pays attention on the innovative therapies, but the generic drug division authorizes a multitude of generic drugs. There’s a biosimilars division, non-prescription drug unit and so forth, and each of these need to be looked after,” she explained. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

There is also, a substantial management component to the job, which manages more than 5,000 personnel. “It’s a massive management job, if you perform it correctly,” the former official said.

Agency Reaction and Disputed Programs

Regarding inquiries about Dr. Høeg's qualifications and whether this selection represents increased cooperation among agency officials on immunizations, a spokesperson said that the “inquiries stem from inaccurate premises”.

“Her experience matches the functions of her job,” the representative said, pointing to the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial one-day medication authorization process that apparently concerned her preceding directors. “By what process are these therapies being chosen for this expedited pathway? Who is making the calls?” Howard asked. “There is a lot of confidentiality occurring at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed oversight of most medications, aside from vaccines.”

Public History on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if concerning, past, some experts have noted. She published a research paper using unverified public submissions to determine the incidence of myocarditis following Covid immunization. She advised the state of Florida top health official Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccinations are riskier than they are.

Among her “wish list” for the current administration included revising guidelines for novel immunizations and ending “optional” immunizations, she remarked after the election on a audio program. At the FDA, Høeg has reportedly suggested preventing teenage boys from obtaining Covid vaccinations.

“She is an all-around true believer who commences with her conclusions and tailors the evidence to fit the data in a extremely deceptive, fraudulent way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of fellow contrarians, {like|